152513-88-7

Basic information

• Product Name: Carbamic acid, 5-azaspiro[2.4]hept-7-yl-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Carbamic acid, 5-azaspiro[2.4]hept-7-yl-, 1,1-dimethylethyl ester (9CI);7-tert-Butoxycarbonylamino-5-azaspiro[2.4]heptane;Tert-butyl 5-azaspiro[2.4]heptan-7-ylcarbamate;CarbaMic acid,-5-azaspiro[2.4]hept-7-yl-, 1,1-diMethylethyl ester;(5-Aza-spiro[2.4]hept-7-yl)-carbamic acid tert-butyl ester
• CAS NO: 152513-88-7
• Molecular Formula: C₁₁H₂₀N₂O₂
• Molecular Weight: 212.2887
• Product Categories: N-BOC
• Mol File: 152513-88-7.mol

Chemical Properties

• Boiling Point: 329.029 °C at 760 mmHg
• Flash Point: 152.791 °C
• Appearance: /
• Density: 1.099 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.513
• PKA: 12.39±0.40(Predicted)
• CAS DataBase Reference: Carbamic acid, 5-azaspiro[2.4]hept-7-yl-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, 5-azaspiro[2.4]hept-7-yl-, 1,1-dimethylethyl ester (9CI)(152513-88-7)
• EPA Substance Registry System: Carbamic acid, 5-azaspiro[2.4]hept-7-yl-, 1,1-dimethylethyl ester (9CI)(152513-88-7)

Safety Data

• Hazardous Substances Data: 152513-88-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Carbamic acid, 5-azaspiro[2.4]hept-7-yl-, 1,1-dimethylethyl ester (9CI) is used as a precursor in the synthesis of various pharmaceutical compounds. Its unique chemical structure and properties make it a valuable component in the development of new drugs.
Used in Organic Synthesis:
Carbamic acid, 5-azaspiro[2.4]hept-7-yl-, 1,1-dimethylethyl ester (9CI) serves as an intermediate in organic synthesis, contributing to the formation of complex organic molecules. Its reactivity and functional groups allow it to participate in various chemical reactions, facilitating the synthesis of target molecules.
Used in Chemical Research:
Carbamic acid, 5-azaspiro[2.4]hept-7-yl-, 1,1-dimethylethyl ester (9CI) is utilized as a reagent in chemical research, enabling scientists to explore its properties and potential applications. Its presence in various chemical reactions can provide insights into its reactivity and interactions with other compounds.
While the specific uses and properties of Carbamic acid, 5-azaspiro[2.4]hept-7-yl-, 1,1-dimethylethyl ester (9CI) may vary depending on the context and the specific application, its versatility and potential in the pharmaceutical, organic synthesis, and chemical research fields make it a valuable compound for further exploration and development.

InChI:InChI=1/C11H20N2O2/c1-10(2,3)15-9(14)13-8-6-12-7-11(8)4-5-11/h8,12H,4-7H2,1-3H3,(H,13,14)

Upstream product

• 129306-04-3 5-benzyl-5-azaspiro[2.4]heptane-4,7-dione 
• 129306-07-6 5-benzyl-5-azaspiro[2.4]heptane-7-amine 
• 129306-06-5 (7E)-5-benzyl-7-(hydroxyimino)-5-azaspiro[2.4]heptan-4-one 
• 129306-13-4 5-phenylmethyl-N-(tert-butoxycarbonyl)-5-azaspiro[2.4]heptane-7-amine 

Downstream Products

• 1000062-33-8 (2S,4S)-2-[7-(t-butyloxycarbonylamino-5-azaspiro[2.4]heptane)carbonyl]-4-tritylthio-1-(allyloxycarbonyl)pyrrolidine 

Relevant articles and documents

Fluoroquinolone derivative and application of fluoroquinolone derivative as antibacterial drug

The invention discloses a fluoroquinolone derivative which is characterized in that the fluoroquinolone derivative has a structure as shown in a general formula (I) or an isomer thereof or a pharmaceutically acceptable salt thereof or a mixture of the structures. Wherein R1 is selected from C1-C4 alkyl groups; or R1 is selected from a spiro or bridged alkane chain which shares one or two carbon atoms with pyrrolidinyl connected with R1, and R1 contains 1-6 carbon atoms; O atom on the benzene ring is alternatively connected with R2 or R3: when the O atom on the benzene ring is connected with R2, R2 is selected from substituted or unsubstituted C2-C4 alkylene, and R3 does not exist; when O atom is connected with R3, R2 is selected from C3-C6 cycloalkyl, and R3 is selected from C1-C3 alkyl. The fluoroquinolone derivative provided by the invention has a good inhibition effect on escherichia coli, staphylococcus aureus and tetracoccus, and provides a certain reference for further design of quinolone compound structures.

Substituted alkynyl pyridine compounds and methods of use thereof, and use thereof

The invention provides a substituted alkynylpyridine compound with a structure represented by a formula (I) as described in the specification and a pharmaceutically acceptable salt and a medicinal preparation thereof. The compound is used for adjusting activity of protein kinase and adjusting intercellular or intracellular signal response. The invention also relates to a pharmaceutical composition including the compound provided by the invention and a method of applying the pharmaceutical composition in treating mammals, especially in treating highly proliferative diseases of the mankind.

SUBSTITUTED ALKYNYL PYRIDINE COMPOUNDS AND METHODS OF USE

The present invention provides novel substituted alkynyl pyridine compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

Synthesis and In-Vitro Activity of Novel 1β-Methylcarbapenems Having Spiro[2,4]heptane Moieties

The synthesis of a new series of 1β-methylcarbapenems having spiro[2,4]heptane moieties is described. Their in-vitro antibacterial activities against both gram-positive and gram-negative bacteria were tested and the effect of substituents on the pyrrolidine ring was investigated. Most compounds were shown to be more active than the compared meropenem and imipenem against Escherichia coli. One particular compound, IIIb, having hydroxy a moiety showed the most potent antibacterial activity.

Optically active pyridonecarboxylic acid derivatives

N1 -(1,2-cis-2-halogenocyclopropyl)-substituted pyridonecarboxylic acid derivatives represented by the following formula (I) the terms of which are defined in the specification and the salts thereof are disclosed: STR1 These compounds have pate

Spiro compound

The present invention relates to spiro compounds of general formula I: STR1 wherein the substituents are herein below defined. The present invention relates to antibacterial spiro compounds which are of value as drugs for humans, veterinary drugs or drugs for use in fish culture or as preservatives, and to antibacterial compositions containing one or more of the same compounds as active ingredients.